//finance.eastmoney.com/a/202511133563845375.html
November 14, 2025
Source: drugdu
75
Beijing Business Daily (Reporter Ding Ning) - On the evening of November 13th, Borui Pharmaceutical...(688166) issued an announcement stating that its wholly-owned subsidiary, Borui Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Borui Pharmaceutical"), recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, agreeing to conduct clinical trials of Borui Pharmaceutical's BGM1812 injection for overweight or obese patients.
Borui Pharmaceuticals stated that, as of the date of this announcement, its BGM1812 injection for weight loss has received FDA approval for clinical trials in the United States, and the first clinical enrollment has been completed. As of the date of this announcement, no similar targeted formulations for weight loss have been approved for marketing globally.
https://finance.eastmoney.com/a/202511133563845375.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
